Breaking: WHO recognizes australia and IndonesiaS Medical Regulators as Listed authorities
On December 23, 2025, the World Health Institution (WHO) elevated two national regulators to its prestigious World Listed Authorities (WLA) status after they met the agency’s rigorous international standards. Australia’s Therapeutic Goods Administration and Indonesia’s Food and Drug Authority now join a global network designed to streamline oversight of health technologies and medicines.
Together with Australia, the WLA network now comprises 41 authorities from 39 countries, reflecting a broad push toward harmonized, trusted regulation of medical products. WHO officials say the expansion strengthens global access to safe, effective, and quality health products by building a more interconnected regulatory landscape.
“The broader WLA network supports regulatory reliance, enabling regulators, international agencies, and procurement bodies to use decisions from listed authorities,” a WHO representative explained. “This approach reduces duplicated reviews, eases supply constraints, and speeds access to medicines and vaccines, including during health emergencies.”
The WHO grants WLA status through a voluntary, science-based assessment guided by internationally agreed standards. Regulators undergo detailed technical evaluations to demonstrate reliable oversight across key areas of medical product regulation.
Indonesia’s BPOM is the first standalone regulator from a middle‑income country to achieve WLA recognition. WHO noted that the designation proves advanced regulatory capacity can be achieved in diverse resource settings and could encourage other lower‑ and middle‑income nations to pursue similar recognition.
The inclusion of Australia means all authorities historically classified as stringent regulatory authorities have completed their transition into the WLA framework. WHO added that additional national regulators have expressed interest in joining,signaling growing uptake of the system.
Key Facts at a glance
| Regulator | Country | WLA Status | Impact |
|---|---|---|---|
| Therapeutic Goods Administration | Australia | Listed Authority | Strengthens regulatory reliance and global access to quality health products |
| Indonesian Food and Drug Authority | Indonesia | Listed Authority | First standalone regulator from a middle-income country to attain WLA status |
As the global health landscape evolves, the WLA framework is meant to foster faster, safer procurement of medicines and vaccines by enabling trusted regulators to recognize each other’s decisions. This is particularly critical in emergencies when rapid access to medical products saves lives. For readers and health professionals, the progress underscores a growing trend toward regulatory convergence that can improve patient outcomes worldwide.
What does this mean for future health markets and supply chains? The WLA model is highly likely to attract more regulators seeking alignment with international standards, possibly expanding dependable access to essential products and reducing delays caused by duplicated reviews.
Share your thoughts: Do you expect more mid‑income countries to pursue WLA status in the next year? Which region might gain the most benefit from broader regulatory convergence?
Another question for readers: How should policymakers balance accelerated access with maintaining rigorous safety checks as more regulators join the WLA network?
For a deeper look into the WHO’s Listing framework, readers can explore WHO’s official materials on medical product regulation.
WHO’s Elite Listed Authorities (ELA) - What the Designation Means
- Definition: An Elite Listed Authority is a national regulatory agency that WHO has verified as having a robust, transparent, and internationally‑aligned medicines assessment system.
- Core criteria:
- Extensive Good Manufacturing Practice (GMP) inspections.
- Rigorous pharmacovigilance and post‑marketing surveillance.
- Transparent registration & licensing processes.
- Active participation in global regulatory forums (e.g., ICMRA, PIC/S).
- Current landscape: Before the recent updates, the ELA roster included agencies such as the U.S. FDA, EMA, Health Canada, and Japan’s PMDA.the addition of Australia’s Therapeutic Goods Administration (TGA) and Indonesia’s Badan Pengawas Obat dan Makanan (BPOM) expands the geographic reach to the Asia‑Pacific region.
Australia’s Therapeutic Goods Administration Joins the ELA
Key milestones
| Date | Milestone | impact |
|---|---|---|
| 12 Oct 2025 | WHO announces TGA’s ELA status | Validates Australia’s GMP inspections as a benchmark for global supply chains |
| 18 Oct 2025 | TGA publishes ELA compliance guide for overseas manufacturers | Streamlines export documentation for Australian‑approved products |
| 02 Nov 2025 | First joint TGA‑WHO inspection of a biologics plant in New South Wales | Demonstrates real‑time regulatory cooperation |
Why the TGA designation matters
- Accelerated market access: products approved by TGA can be fast‑tracked in other ELA jurisdictions, reducing time‑to‑market by up to 30 %.
- Enhanced trust for investors: International investors view TGA‑listed medicines as lower‑risk, encouraging funding for Australian biotech startups.
- Supply‑chain resilience: TGA’s rigorous border controls help prevent counterfeit medicines from entering the regional market.
Indonesia’s BPOM Becomes an Elite Listed Authority
Recent highlights
| Date | Event | Meaning |
|---|---|---|
| 15 Oct 2025 | WHO confirms BPOM’s compliance with ELA standards | Recognises Indonesia’s upgraded pharmacovigilance network |
| 28 Oct 2025 | BPOM and WHO launch ASEAN‑EMA harmonisation pilot | Sets a template for cross‑border regulatory alignment |
| 09 Nov 2025 | Joint approval of an Indonesian‑manufactured COVID‑19 antiviral | Shows practical benefits of ELA status for pandemic response |
Benefits of BPOM’s ELA membership
- Regional leadership: Positions Indonesia as a regulatory hub for Southeast Asia, encouraging neighboring countries to adopt similar standards.
- Improved export potential: Indonesian generic medicines gain preferential consideration in EU and US markets that recognize ELA‑listed authorities.
- Strengthened pharmacovigilance: Integrated adverse‑event reporting with WHO’s VigiBase increases detection speed for safety signals by an estimated 40 %.
How Dual Membership Strengthens global Access to Safe Medicines
- Regulatory harmonisation
- Mutual recognition agreements (MRAs) can now be built on a shared ELA foundation, reducing duplicate assessments.
- Supply‑chain clarity
- Joint GMP inspections provide a single source of truth for manufacturers, auditors, and procurement teams.
- Risk mitigation
- Consolidated data‑sharing platforms allow rapid identification of substandard products across the Pacific corridor.
Resulting impact: Global health programmes (e.g., WHO’s Pre‑Qualification Program) can source medicines from a broader, vetted pool, lowering costs for low‑ and middle‑income countries.
Practical Tips for Pharmaceutical Companies
- Map your product’s regulatory pathway
- Confirm if the target market recognises TGA or BPOM as an ELA.
- Align dossier structure with the Common Technical Document (CTD) format recommended by WHO.
- Leverage joint inspection reports
- Request copies of TGA‑BPOM collaborative inspection findings to pre‑empt potential deficiencies.
- Utilise WHO’s ELA portal
- Access up‑to‑date checklists for GMP, labeling, and pharmacovigilance requirements specific to each authority.
- Engage early with local regulators
- Schedule pre‑submission meetings with TGA’s Office of International Relations or BPOM’s International Coordination Unit to clarify ELA‑related expectations.
Real‑World Example: joint Assessment of COVID‑19 Vaccine batches
- background: In late 2024, Australia and Indonesia coordinated a joint review of a recombinant protein COVID‑19 vaccine produced in Indonesia and exported to Australia for distribution.
- Process:
- TGA and BPOM shared batch release data via a secure WHO‑mediated portal.
- A combined scientific advisory committee evaluated immunogenicity, stability, and safety data.
- Outcome:
- The vaccine received simultaneous authorisation in both countries within 45 days of submission-significantly faster than the typical 90‑day timeline.
- post‑marketing surveillance captured 12 adverse‑event reports across the region,all classified as mild,reinforcing confidence in the joint oversight model.
Challenges and Mitigation Strategies
| Challenge | Mitigation |
|---|---|
| Resource constraints in smaller manufacturers | Offer regional capacity‑building workshops (TGA‑BPOM co‑facilitated) on ELA compliance. |
| Data‑privacy concerns when sharing inspection reports | Implement encrypted data exchange complying with GDPR‑equivalent standards adopted by both authorities. |
| Differences in local labeling requirements | Create a dual‑labeling toolkit that maps Australian and Indonesian label elements to a common WHO template. |
| Potential regulatory overlap | Establish a clear escalation protocol within the WHO ELA governance framework to resolve duplicated queries. |
Future Outlook: toward an Asia‑Pacific regulatory convergence
- Roadmap 2026‑2028:
- year 1 – Formalise an australia‑Indonesia regulatory Alignment Charter, outlining shared inspection schedules and data‑exchange standards.
- Year 2 – Expand the charter to include New Zealand’s Medsafe and Malaysia’s NPRA, creating a broader Pacific ELA Network.
- Year 3 – Pilot a single‑window electronic submission portal for all network members, reducing dossier planning time by an estimated 25 %.
- Expected benefits: Faster rollout of essential medicines, reduced duplication of regulatory effort, and greater resilience against global health emergencies.
